Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Verastem Inc (NQ: VSTM ) 2.870 +0.100 (+3.61%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Verastem Inc < Previous 1 2 3 4 5 6 7 8 Next > What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday? May 24, 2024 Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant... Via Benzinga Exposures Product Safety Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket May 24, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session May 24, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday May 24, 2024 We're diving into the biggest pre-market stock movers that traders need to know about on Friday morning with all of the latest news! Via InvestorPlace VSTM Stock Earnings: Verastem Beats EPS for Q1 2024 May 09, 2024 VSTM stock results show that Verastem beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Recap: Verastem Q4 Earnings March 14, 2024 Via Benzinga Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer May 24, 2024 From Verastem Oncology Via Business Wire Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer May 23, 2024 From Verastem Oncology Via Business Wire Where Verastem Stands With Analysts November 15, 2023 Via Benzinga Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates May 09, 2024 From Verastem Oncology Via Business Wire Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference May 07, 2024 From Verastem Oncology Via Business Wire Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer April 18, 2024 From Verastem Oncology Via Business Wire Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 04, 2024 From Verastem Oncology Via Business Wire Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer March 18, 2024 From Verastem Oncology Via Business Wire VSTM Stock Earnings: Verastem Misses EPS for Q4 2023 March 14, 2024 VSTM stock results show that Verastem missed analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates March 14, 2024 From Verastem Oncology Via Business Wire Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs March 11, 2024 From Verastem Oncology Via Business Wire Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer March 05, 2024 From Verastem Oncology Via Business Wire Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024 March 05, 2024 From Verastem Oncology Via Business Wire 3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024 February 07, 2024 Discover AI's top stock selections, meticulously analyzed for 2024, promising more than just returns but a revolution in your portfolio. Via InvestorPlace Topics Artificial Intelligence Exposures Artificial Intelligence Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session February 12, 2024 Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and... Via Benzinga Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers January 29, 2024 From Verastem Oncology Via Business Wire Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) January 18, 2024 From Verastem Oncology Via Business Wire Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference January 11, 2024 From Verastem Oncology Via Business Wire Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 05, 2024 From Verastem Oncology Via Business Wire Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics December 18, 2023 From Verastem Oncology Via Business Wire 3 Off-the-Beaten-Path Stocks Poised for Substantial Growth December 13, 2023 Although there’s safety in numbers, many times, you need to consider uncommon stocks to buy for growth for robust upside. Via InvestorPlace Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer December 13, 2023 From Verastem Oncology Via Business Wire Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential December 03, 2023 Although even so-called penny stocks with potential carry dramatic risks, these four-baggers benefit from analyst backing. Via InvestorPlace New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach November 13, 2023 From Verastem Oncology Via Business Wire < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.